<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97354">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01779557</url>
  </required_header>
  <id_info>
    <org_study_id>HR-PD-2012</org_study_id>
    <secondary_id>ChiCTR-TRC-13003001</secondary_id>
    <nct_id>NCT01779557</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of Two Kinds of Peritoneal Dialysate</brief_title>
  <acronym>SEED</acronym>
  <official_title>The Prospective, Randomized, Parallel, Controlled, Multi-center Clinical Study of Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy and safety of Huaren Peritoneal Dialysate and Baxter
      Peritoneal Dialysate, investigate the proper dialysis dose for Chinese CAPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, parallel, controlled, multi-center clinical study
      of Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate.It aims to  investigate the
      proper dialysis dose for Chinese CAPD patients.At the same time,it can evaluate the efficacy
      and safety of Chinese product Huaren Peritoneal Dialysate and peritoneal dialysis product
      Baxter Peritoneal Dialysate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>survival rate</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD technique survival rate, estimated glomerular filtration rate, normalized protein catabolic rate,</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Kidney Failure,Chronic</condition>
  <arm_group>
    <arm_group_label>Huaren peritoneal dialysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Huaren Peritoneal dialysate CAPD 3-5 times/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baxter Peritoneal Dialysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baxter Peritoneal dialysate CAPD 3-5 times/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huaren Peritoneal Dialysate</intervention_name>
    <description>Huaren Peritoneal dialysate CAPD 3-5 times/d</description>
    <arm_group_label>Huaren peritoneal dialysate</arm_group_label>
    <other_name>Huaren Peritoneal Dialysate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baxter Peritoneal Dialysate</intervention_name>
    <description>Baxter Peritoneal dialysate CAPD 3-5 times/d</description>
    <arm_group_label>Baxter Peritoneal Dialysate</arm_group_label>
    <other_name>Baxter Peritoneal Dialysate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18, male or female

          -  Patients with end stage renal diseases

          -  Dialysis mode: CAPD

          -  Dialysis duration:≥30 days and ≤6 months

          -  Be capable of implementing home dialysis

          -  Diabetic nephropathy, 3ml/min≤ residual renal GFR ≤15ml/min; other renal diseases,
             3ml/min≤ residual renal GFR ≤10ml/min

          -  Sign the written informed consent

        Exclusion Criteria:

          -  Acute renal failure

          -  Planing to receive kidney transplantation in 2 years

          -  Hemodialysis

          -  Exit site infection or tunnel infection

          -  Presenting 2/3 of the following: a. abdominal pain, turbid ascites, with or without
             fever; b. drainage fluid WBC＞100×106/L, neutrophil ratio＞50%; c.culture positive/
             Gram stain positive in drainage fluid;

          -  Anti-HIV positive

          -  Allergic to components of dialysate

          -  Active, residual malignant tumor, or systemic infection, liver cirrhosis, severe
             congestive heart failure, anemia（Hb&lt;80g/L）,malnutrition（Serum Alb&lt;28g/L）,refractory
             hypertension

          -  Identified peritoneal high transportation by peritoneal equilibration test (PET)

          -  Extreme body shape (height&gt; 185cm or height &lt;145cm), obesity (BMI ≥ 33kg/m2)

          -  Poor compliance

          -  Pregnant or lactating, women of childbearing age do not agree to use effective
             contraceptive measures during the trial

          -  Has a history of alcoholism and drug abuse (defined as illegal drugs)

          -  Any circumstances when patients are believed unsuitable for this trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHEN Xiangmei, yes</last_name>
    <role>Study Director</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZHOU Jianhui, Doctor</last_name>
      <phone>+86 010 66935462</phone>
      <email>china_pd@126.com</email>
    </contact>
    <contact_backup>
      <last_name>CHEN Xiangmei, Doctor</last_name>
      <phone>+86 010 66935462</phone>
      <email>xmchen301@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.301hospital.com.cn/</url>
    <description>The website of PLA general hospital</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Chen Xiangmei</investigator_full_name>
    <investigator_title>Professor, Chief physician, Academician of  Chinese Academy of Engineering</investigator_title>
  </responsible_party>
  <keyword>CAPD</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>survival rate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
